cas 3034-22-8|| where to buy 5-bromo-1,3-thiazol-2-amine

Produktname:5-bromo-1,3-thiazol-2-amine

IUPAC Name:5-bromo-1,3-thiazol-2-amine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM104786-25g	in stock	Ǹƚ
CM104786-100g	in stock	ĳǎǎ
CM104786-500g	in stock	ŌŤƴ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3034-22-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3034-22-8; Molekulare Formel:C3H3BrN2S; Schmelzpunkt:-; SMILES-Code:NC1=NC=C(Br)S1; Dichte:

: Katalognummer:CM104786; Molekulargewicht:179.04; Siedepunkt:; Mdl-Nr.:MFCD00016893; Lagerung:

: Thiazoles; Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

: Cadisegliatin; vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.